An open trial of paroxetine in the treatment of children and adolescents diagnosed with dysthymia

J Child Adolesc Psychopharmacol. 2000 Summer;10(2):103-9. doi: 10.1089/cap.2000.10.103.

Abstract

This open-label study examined the potential efficacy of paroxetine in the treatment of children and adolescents diagnosed with dysthymia over a period of 3 months. Seven subjects were evaluated by the Hamilton Depression Rating Scale (HAM-D), by the Clinical Global Impression Severity of Illness Scale (CGI-S), and the Clinical Global Impression Improvement Scale (CGI-I). Seventy-one percent of patients had a satisfactory response, suggesting the efficacy of paroxetine in children with dysthymia.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antidepressive Agents, Second-Generation / adverse effects
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Child
  • Dysthymic Disorder / drug therapy*
  • Dysthymic Disorder / psychology
  • Female
  • Humans
  • Male
  • Nausea / chemically induced
  • Pain / chemically induced
  • Paroxetine / adverse effects
  • Paroxetine / therapeutic use*
  • Psychiatric Status Rating Scales

Substances

  • Antidepressive Agents, Second-Generation
  • Paroxetine